Stay updated on Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FbpRD-bkVdKqZmngDyG3cpbNI7kw.uncropped.jpg&w=3840&q=75)
Latest updates to the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0 and now includes 2 locations, replacing the previous version v2.9.7.SummaryDifference0.2%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent change in the webpage content version.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Drug Information available for: Pembrolizumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Single Arm Assignment Pembrolizumab + External Beam Radiation Therapy Drug : Pembrolizumab 200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered. Other Names: Keytruda Radiation : External Beam Radiation Therapy 20-30 Gy over five fractions for up to two cycles.' This change represents an update in the drug information and study details related to the use of Pembrolizumab in combination with External Beam Radiation Therapy for the treatment of Carcinoma of Unknown Primary (CUP) patients.SummaryDifference28%
Stay in the know with updates to Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page.